Top Markets
Coin of the day
Biocure Technology Inc. Biocure Technology Inc.

Biocure Technology Inc.

CURE
Classifica tra le azioni #39915
Biocure Technology Inc., operating with its subsidiary, focuses on the creation... Biocure Technology Inc., operating with its subsidiary, focuses on the creation and market introduction of biopharmaceutical innovations, particularly those involving recombinant technologies and ranibizumab. The company's current development pipeline includes: Interferons-ß, aimed at treating multiple sclerosis. Ranibizumab, a monoclonal antibody fragment designed to address macular degeneration and a related eye condition known as macular edema. Filgrastim, which targets neutropenia – a deficiency of white blood cells that can arise from cancer, bone marrow transplants, chemotherapy, or other medical issues. Additionally, Biocure is conducting research and development into several promising areas: CAR T-cell therapy, which works by identifying and eradicating cancer cells. A vaccine against foot and mouth disease. Various products for promoting hair growth. The firm was established in 2005 and its corporate headquarters are located in Vancouver, Canada.
Prezzo delle azioni
$0.00366968
Ultima sincronizzazione: 2024-07-12
Capitalizzazione di mercato
$299.46K
Variazione (1 giorno)
-66.77%
Variazione (1 anno)
0.00%
Paese
CA
Scambia Biocure Technology Inc. (CURE)

Categoria

Rapporto P/S per Biocure Technology Inc. (CURE)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Biocure Technology Inc., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Biocure Technology Inc. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE